WO2000054803A3 - Immunostimulatory nucleic acids and antigens - Google Patents

Immunostimulatory nucleic acids and antigens Download PDF

Info

Publication number
WO2000054803A3
WO2000054803A3 PCT/US2000/007213 US0007213W WO0054803A3 WO 2000054803 A3 WO2000054803 A3 WO 2000054803A3 US 0007213 W US0007213 W US 0007213W WO 0054803 A3 WO0054803 A3 WO 0054803A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigens
antigen
fragments
present
nucleic acids
Prior art date
Application number
PCT/US2000/007213
Other languages
French (fr)
Other versions
WO2000054803A2 (en
Inventor
Howard B Sosin
Michael J Caplan
Original Assignee
Panacea Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Pharm Llc filed Critical Panacea Pharm Llc
Priority to AU37601/00A priority Critical patent/AU3760100A/en
Publication of WO2000054803A2 publication Critical patent/WO2000054803A2/en
Publication of WO2000054803A3 publication Critical patent/WO2000054803A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/38—Antigens from snakes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides methods and compositions for modulating an individual's immune response to antigens. It is an aspect of the present invention that allergic responses to antigens, which in some cases lead to asthma and even anaphylaxis, can be treated or prevented by administering compositions having immunostimulatory oligonucleotides having unmethylated CpG sequences. It is another aspect of the present invention that allergies to antigens, especially one that result in asthma and anaphylaxis, can be treated or prevented by administering compositions containing immunostimulatory oligonucleotides having unmethylated CpG dinucleotide sequences and further comprising antigen(s), fragments of the antigen, mixtures of fragments of the antigen, antigens modified to reduce Th2-type immune responses, and fragments of the antigen modified to reduce Th2-type immune responses. Cellular systems for studying immunostimulation by CpG containing nucleic acids include in vivo, in vitro or ex vivo systems.
PCT/US2000/007213 1999-03-16 2000-03-16 Immunostimulatory nucleic acids and antigens WO2000054803A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU37601/00A AU3760100A (en) 1999-03-16 2000-03-16 Immunostimulatory nucleic acids and antigens

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12459599P 1999-03-16 1999-03-16
US60/124,595 1999-03-16
US12507199P 1999-03-17 1999-03-17
US60/125,071 1999-03-17

Publications (2)

Publication Number Publication Date
WO2000054803A2 WO2000054803A2 (en) 2000-09-21
WO2000054803A3 true WO2000054803A3 (en) 2001-01-11

Family

ID=26822754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/007213 WO2000054803A2 (en) 1999-03-16 2000-03-16 Immunostimulatory nucleic acids and antigens

Country Status (2)

Country Link
AU (1) AU3760100A (en)
WO (1) WO2000054803A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028845B2 (en) 2001-06-21 2015-05-12 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same-IV
US9382545B2 (en) 2006-09-27 2016-07-05 Coley Pharmaceutical Gmbh CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
EP1733735B1 (en) 1998-05-22 2017-03-22 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
EP2204186B1 (en) 1999-02-17 2016-04-06 CSL Limited Immunogenic complexes and methods relating thereto
ATE419869T1 (en) 1999-08-19 2009-01-15 Dynavax Tech Corp METHOD FOR MODULATING AN IMMUNE RESPONSE USING IMMUNSTIMULATIVE SEQUENCES AND COMPOSITIONS THEREOF
AP1775A (en) * 1999-09-25 2007-08-28 Univ Iowa Res Found Immunostimulatory nucleic acids.
US20020018778A1 (en) * 1999-12-06 2002-02-14 Caplan Michael J. Passive desensitization
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
CA2403292C (en) * 2000-04-06 2011-02-08 Panacea Pharmaceuticals, Llc Microbial delivery system
EP1364010B1 (en) 2000-12-27 2010-06-16 Dynavax Technologies Corporation Immunomodulatory polynucleotides and methods of using the same
US20030133988A1 (en) 2001-08-07 2003-07-17 Fearon Karen L. Immunomodulatory compositions, formulations, and methods for use thereof
DK1450856T3 (en) 2001-09-14 2010-05-31 Cytos Biotechnology Ag Packaging of Immunostimulatory CpG in Virus-Like Particles, Method and Use
US7741297B2 (en) 2002-02-04 2010-06-22 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
ZA200503511B (en) 2002-10-29 2006-10-25 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
EP1575977B1 (en) 2002-12-23 2009-09-09 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
CN101454451A (en) * 2003-10-30 2009-06-10 科勒制药有限公司 C-class oligonucleotide analogs with enhanced immunostimulatory potency
US8057800B2 (en) * 2004-06-10 2011-11-15 Circassia Limited Immunointeractive molecules and uses thereof
AU2005252268B2 (en) * 2004-06-10 2012-06-28 Aravax Pty Limited Novel immunointeractive molecules and uses thereof
AU2006325225B2 (en) 2005-12-14 2013-07-04 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US8541559B2 (en) 2006-06-12 2013-09-24 Cytos Biotechnology Ag Process for producing aggregated oligonucleotides
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
CA2889784A1 (en) 2012-10-30 2014-05-08 Monash University Novel immunotherapeutic molecules and uses thereof
AU2014248090B2 (en) 2013-04-03 2018-08-02 N-Fold Llc Novel nanoparticle compositions
KR20160075532A (en) 2013-09-25 2016-06-29 아라백스 피티와이 엘티디 Novel immunotherapeutic composition and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984000110A1 (en) * 1980-02-19 1984-01-19 J Gabriel Michael Polypeptide active immunosuppressant fraction
US5804201A (en) * 1996-03-11 1998-09-08 The Rockefeller University Immunomodulatory peptides of vespid antigen 5
WO1998055495A2 (en) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984000110A1 (en) * 1980-02-19 1984-01-19 J Gabriel Michael Polypeptide active immunosuppressant fraction
US5804201A (en) * 1996-03-11 1998-09-08 The Rockefeller University Immunomodulatory peptides of vespid antigen 5
WO1998055495A2 (en) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KLINMAN DENNIS M ET AL: "CpG motifs as immune adjuvants.", VACCINE, vol. 17, no. 1, January 1999 (1999-01-01), pages 19 - 25, XP004139028, ISSN: 0264-410X *
KRIEG A M ET AL: "CPG MOTIFS IN BACTERIAL DNA TRIGGER DIRECT B-CELL ACTIVATION", NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 374, 6 April 1995 (1995-04-06), pages 546 - 549, XP000197060, ISSN: 0028-0836 *
STANLEY J STEVEN ET AL: "Identification and mutational analysis of the immunodominant IgE binding epitopes of the major peanut allergen Ara h 2.", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 342, no. 2, 1997, pages 244 - 253, XP000946317, ISSN: 0003-9861 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028845B2 (en) 2001-06-21 2015-05-12 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same-IV
US9382545B2 (en) 2006-09-27 2016-07-05 Coley Pharmaceutical Gmbh CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity

Also Published As

Publication number Publication date
AU3760100A (en) 2000-10-04
WO2000054803A2 (en) 2000-09-21

Similar Documents

Publication Publication Date Title
WO2000054803A3 (en) Immunostimulatory nucleic acids and antigens
WO1996010419A3 (en) Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
WO2001093902A3 (en) Immunostimulatory rna/dna hybrid molecules
WO2004087203A3 (en) Immunostimulatory nucleic acid oil-in-water formulations for topical application
WO2004053104A3 (en) 5’ cpg nucleic acids and methods of use
WO1996011279A3 (en) Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
WO1998055495A3 (en) Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO2001051083A3 (en) Innate immunity-stimulating compositions of cpg and saponin and methods thereof
AU7621600A (en) Human rnase h and oligonucleotide compositions thereof
NZ546475A (en) C-Class oligonucleotide analogs with enhanced immunostimulatory potency
WO2003024392A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003000113A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004043407A3 (en) Methods and products for treating staphylococcal infections
ATE326239T1 (en) METHODS FOR TREATING IG-E ASSOCIATED DISEASES AND COMPOSITIONS FOR USE IN SUCH METHODS
AU7743100A (en) Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
WO2006110760A3 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2002312303A1 (en) Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
SG167667A1 (en) Nucleic acid compositions for stimulating immune responses
WO2003016915A8 (en) Tumor specific oligosaccharide sequences and use thereof
AU2003304145A1 (en) Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus borrelia
WO2002047613A3 (en) Immunogenic cancer peptides and uses thereof
WO1999058639A3 (en) Structural proteins of fish pancreatic disease virus and uses thereof
ATE472336T1 (en) COMPOSITIONS AND METHODS FOR ACTIVATE YOUR OWN AND ALLERGIC IMMUNITY
AU2002245143A1 (en) Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of chlamydia psittaci
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase